Epigenetic biomarkers and breast cancer: Cause for optimism

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6591-6593

  Visvanathan, Kala ^a,b   Sukumar, Saraswati ^a   Davidson, Nancy E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CYCLIN D2; DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHROMOSOME 3P; CPG ISLAND; CYTOPATHOLOGY; DNA DETERMINATION; DNA METHYLATION; EDITORIAL; EPIGENETICS; GENE INTERACTION; GENE SILENCING; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MODIFICATION;

BREAST NEOPLASMS; CARCINOMA; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 33845309103     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2001     Document Type: Editorial

References (22)

1. Waddington CH. The epigenotype. Endeavour 1942;1: 18-20.
2. Hotchkiss RD. The quantitative separation of purines, pyrimidines, and nucleosides by paper chromatography. J Biol Chem 1948;175:315-32.
3. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter methylation. N Engl J Med 2003;349:2042-54.
4. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-9.
5. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3σ (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
6. Veeck J, Niederacher D, An H, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006;25:3479-88.
7. Martens JW, Nimmrich I, Koenig T, et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005;65:4101-17.
8. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64:3807-13.
9. Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clinical Cancer Research 2006;12:6626-36.
10. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.
11. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
12. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast, and ovarian tumours. Oncogene 2001;20:1509-18.
13. Honorio S, Agathanggelou A, Schuermann M, et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;22:147-50.
14. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006;12:3306-10.
15. Krassenstein R, Sauter E, Dulaimi E, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004;10:28-32.
16. Yeo W, Wong WL, Wong N, Law BK, Tse GM, Zhong S. High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology 2005;37:125-30.
17. Chen CM, Chen HL, Hsiau TH, et al. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol 2003;163:37-45.
18. Fackler MJ, McVeigh M, Mehrotra J, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004;64:4442-52.
19. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001;357:1335-6.
20. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005;12:185-213.
21. Lewis CM, Cler LR, Bu DW, et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005;11:166-72.
22. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:154-5.